Fsd Pharma Class Stock Analysis
| HUGE Stock | USD 0.46 0 0.22% |
FSD Pharma Class is overvalued with Real Value of 0.44 and Hype Value of 0.44. The main objective of FSD Pharma stock analysis is to determine its intrinsic value, which is an estimate of what FSD Pharma Class is worth, separate from its market price. There are two main types of FSD Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect FSD Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of FSD Pharma's stock to identify patterns and trends that may indicate its future price movements.
The FSD Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. FSD Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. FSD Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and FSD Pharma's ongoing operational relationships across important fundamental and technical indicators.
FSD |
FSD Stock Analysis Notes
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.82. Some equities with similar Price to Book (P/B) outperform the market in the long run. FSD Pharma Class recorded a loss per share of 0.46. The entity last dividend was issued on the 16th of October 2019. The firm had 1:201 split on the 16th of October 2019. FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about FSD Pharma Class call Rupert Haynes at 416 854 8884 or check out https://www.fsdpharma.com.FSD Pharma Class Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. FSD Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding FSD Pharma Class or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| FSD Pharma Class generated a negative expected return over the last 90 days | |
| FSD Pharma Class has some characteristics of a very speculative penny stock | |
| FSD Pharma Class has high historical volatility and very poor performance | |
| Net Loss for the year was (18.56 M) with loss before overhead, payroll, taxes, and interest of (3.33 M). | |
| FSD Pharma Class currently holds about 31.62 M in cash with (11.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| FSD Pharma Class has a frail financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from techtimes.com: Sky Rolls Out Huge Upgrades For TV Viewers that Football Fans Will Surely Love |
FSD Pharma Class Upcoming and Recent Events
Earnings reports are used by FSD Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to FSD Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
FSD Largest EPS Surprises
Earnings surprises can significantly impact FSD Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.14 | -0.03 | 0.11 | 78 | ||
2021-03-16 | 2020-12-31 | -0.7 | -0.34 | 0.36 | 51 | ||
2020-08-07 | 2020-06-30 | -1.11 | -0.67 | 0.44 | 39 |
FSD Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as FSD Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading FSD Pharma Class backward and forwards among themselves. FSD Pharma's institutional investor refers to the entity that pools money to purchase FSD Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2023-12-31 | 1.0 | Ground Swell Capital, Llc | 2023-12-31 | 0.0 | Jane Street Group, Llc | 2023-12-31 | 0.0 | Janney Montgomery Scott Llc | 2023-12-31 | 0.0 | The Toronto-dominion Bank | 2023-12-31 | 0.0 | Your Advocates Ltd., Llp | 2023-12-31 | 0.0 | Hrt Financial Llc | 2023-12-31 | 0.0 | Advisorshares Investments, Llc | 2023-12-31 | 270.3 K | Renaissance Technologies Corp | 2023-12-31 | 69.2 K | Scotia Capital Inc | 2023-12-31 | 61.3 K | Ubs Group Ag | 2023-12-31 | 26.4 K |
FSD Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate FSD Pharma's market, we take the total number of its shares issued and multiply it by FSD Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.FSD Profitablity
FSD Pharma's profitability indicators refer to fundamental financial ratios that showcase FSD Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, FSD Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, FSD Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of FSD Pharma's profitability requires more research than a typical breakdown of FSD Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.54) | (1.62) | |
| Return On Capital Employed | (1.55) | (1.47) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (1.41) | (1.34) |
Management Efficiency
FSD Pharma Class has return on total asset (ROA) of (0.4302) % which means that it has lost $0.4302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8391) %, meaning that it created substantial loss on money invested by shareholders. FSD Pharma's management efficiency ratios could be used to measure how well FSD Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -1.62. The current year's Return On Capital Employed is expected to grow to -1.47. At present, FSD Pharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.6 M, whereas Other Current Assets are forecasted to decline to about 146.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.33 | 0.32 | |
| Net Current Asset Value | 2.9 M | 3.1 M | |
| Tangible Asset Value | 8.9 M | 9.3 M | |
| Tangible Book Value Per Share | 0.19 | 0.18 | |
| Enterprise Value Over EBITDA | (1.96) | (2.05) | |
| Price Book Value Ratio | 2.77 | 2.90 | |
| Enterprise Value Multiple | (1.96) | (2.05) | |
| Price Fair Value | 2.77 | 2.90 | |
| Enterprise Value | 34 M | 32.3 M |
The analysis of FSD Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze FSD Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of FSD Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.914 |
Technical Drivers
As of the 25th of April, FSD Pharma shows the mean deviation of 3.01, and Standard Deviation of 4.3. FSD Pharma Class technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for FSD Pharma Class, which can be compared to its peers. Please confirm FSD Pharma Class variance, as well as the relationship between the maximum drawdown and skewness to decide if FSD Pharma Class is priced adequately, providing market reflects its regular price of 0.459 per share. As FSD Pharma Class is a penny stock we also recommend to verify its jensen alpha numbers.FSD Pharma Class Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. FSD Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for FSD Pharma Class. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
FSD Pharma Predictive Daily Indicators
FSD Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of FSD Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
FSD Pharma Forecast Models
FSD Pharma's time-series forecasting models are one of many FSD Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary FSD Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About FSD Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how FSD Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling FSD shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as FSD Pharma. By using and applying FSD Stock analysis, traders can create a robust methodology for identifying FSD entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (232.65) | (244.29) | |
| Operating Profit Margin | (164.02) | (172.23) | |
| Net Loss | (234.03) | (245.73) | |
| Gross Profit Margin | (8.43) | (8.85) |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding FSD Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in FSD Pharma Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the FSD Pharma Class information on this page should be used as a complementary analysis to other FSD Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for FSD Stock analysis
When running FSD Pharma's price analysis, check to measure FSD Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FSD Pharma is operating at the current time. Most of FSD Pharma's value examination focuses on studying past and present price action to predict the probability of FSD Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FSD Pharma's price. Additionally, you may evaluate how the addition of FSD Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is FSD Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FSD Pharma. If investors know FSD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FSD Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Quarterly Revenue Growth (0.07) | Return On Assets (0.43) | Return On Equity (0.84) |
The market value of FSD Pharma Class is measured differently than its book value, which is the value of FSD that is recorded on the company's balance sheet. Investors also form their own opinion of FSD Pharma's value that differs from its market value or its book value, called intrinsic value, which is FSD Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FSD Pharma's market value can be influenced by many factors that don't directly affect FSD Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FSD Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if FSD Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FSD Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.